RT Journal Article
SR Electronic
T1 Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non–Small Cell Lung Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1081
OP 1086
DO 10.2967/jnumed.113.130674
VO 55
IS 7
A1 Matthijs H. van Gool
A1 Tjeerd S. Aukema
A1 Eva E. Schaake
A1 Herman Rijna
A1 Renato A. Valdés Olmos
A1 Renée van Pel
A1 Sjaak A. Burgers
A1 Harm van Tinteren
A1 Houke M. Klomp
YR 2014
UL http://jnm.snmjournals.org/content/55/7/1081.abstract
AB The purpose of this study was to prospectively evaluate the timing of metabolic response monitoring with 18F-FDG PET of (neoadjuvant) erlotinib treatment in patients with early-stage non–small cell lung cancer. Methods: This study was designed as an open-label phase II trial performed in 4 hospitals in The Netherlands. Patients received preoperative erlotinib (150 mg) once daily for 3 wk. Response evaluation was performed after 4–7 d and at 3 wk with 18F-FDG PET/CT scans. Tumor 18F-FDG uptake and changes were measured as standardized uptake values (SUVs). The metabolic response was classified on the basis of European Organization for Research and Treatment of Cancer criteria (>25% decrease in the maximum SUV) and was compared with histopathologic regression as observed in the resection specimen. Results: From December 2006 to November 2010, 60 patients with non–small cell lung cancer eligible for surgical resection were enrolled in this study. For 43 patients (18 men and 25 women), baseline 18F-FDG PET/CT scans as well as both monitoring scans and histopathologic response monitoring were available. A partial metabolic response on 18F-FDG PET/CT scans was observed for 10 patients (23%) after 1 wk and for 14 patients (33%) after 3 wk. Histopathologic examination revealed regression (necrosis of >50%) in 11 patients (26%). In these patients, the maximum SUV decreased by a mean of 17% within 1 wk and a mean of 31% at 3 wk. Seven patients were identified as responders within 1 wk. Conclusion: Response monitoring with 18F-FDG PET/CT within 1 wk after the start of erlotinib treatment identified approximately 64% of histopathologic responders on the basis of European Organization for Research and Treatment of Cancer criteria.